The Full Wiki

More info on Dexlansoprazole

Dexlansoprazole: Wikis

Advertisements
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Dexlansoprazole
Systematic (IUPAC) name
(R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
Identifiers
CAS number 138530-94-6
ATC code none
Chemical data
Formula C16H14F3N3O2S 
Mol. mass 369.363 g/mol
SMILES eMolecules & PubChem
Therapeutic considerations
Licence data

US FDA:link

Pregnancy cat. B(US)
Legal status -only (US)
Routes Oral

Dexlansoprazole (INN, trade name Kapidex) is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals. Chemically, it is an enantiomer of lansoprazole. The compound was launched in the US for use in the treatment and maintenance of patients with erosive oesophagitis and non-erosive gastro-oesophageal reflux disease (GERD or GORD).[1] Dexlansoprazole was approved by the U.S. Food and Drug Administration (FDA) on January 30, 2009.[1]

Pharmacokinetics

After racemic lansoprazole is applied orally, 80% of the circulating drug are dexlansoprazole. Moreover, both enantiomers have a similar effect on the proton pump.[2] Consequently, the main advantage of Kapidex is not the enantiopure substance, but the pharmaceutical formulation.

Kapidex is based on a dual release technology, with the first quick release producing a plasma peak concentration about one hour after application, and the second retarded release producing another peak about four hours later.[1][3] As of November 2009, clinical relevance of this form of release has yet to be shown.

References

  1. ^ a b c FDA Approves KAPIDEX (dexlansoprazole) delayed release capsules for the Treatment of GERD
  2. ^ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009
  3. ^ Metz, DC; Vakily, M; Dixit, T; Mulford, D (1 May 2009). "Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy". Aliment Pharmacol Ther 29 (9): 928–37. doi:10.1111/j.1365-2036.2009.03984.x. PMID 19298580. 

External links

Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message